Cardinal Health reported fourth-quarter fiscal 2026 results that beat expectations, but a significant portion of the earnings jump came from a one-time tariff refund. Non-GAAP diluted EPS rose 40% year over year to $2.91, with about $0.31 of that gain tied to a $100 million net benefit from IEEPA tariff refunds in the Global Medical Products and Distribution segment. Full-year adjusted free cash flow reached $5 billion, and the board authorized a $5 billion increase to its buyback program, bringing total authorization to $6.4 billion. However, guidance for fiscal 2027 points to slower growth, with Pharma segment revenue expected to rise just 3% to 5%, and GMPD's first quarter projected at roughly half of last year's level due to currency effects and distributor purchase timing. The company also flagged risks from Iran-related conflicts and rising fuel and commodity costs that could pressure GMPD profit.
Cardinal Health IncBeat earnings and increased buyback program by $5 billion, boosting shareholder returns.
